Radiological features of supratentorial gliomas are associated with their genetic aberrations

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109 Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P, Wrensch M (2000) Discrepancies in diagnoses of neuroepithelial neoplasms. Cancer 88:2342–2349 Nagarajan RP, Costello JF (2009) Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 6:436–446 Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD (2005) The molecular epidemiology of gliomas in adults. Neurosurg Focus 19:1–11 Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Wainman N, Eisenhauer E (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013 van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812 Kleihues P, Cavenee WK (eds) (2000) World Health Organization classification of tumors of the nervous system. IARC/WHO, Lyon Hirose Y, Aldape K, Takahashi M, Berger MS, Feuerstein BG (2001) Tissue micro- dissection and degenerate oligonucleotide primed polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 3(2):62–67 Mohapatra G, Moore DH, Kim DH, Grewal L, Hyun WC, Waldman FM, Pinkel D, Fueuerstein BG (1997) Analyses of brain tumor cell lines confirm a simple model of relationships among fluorescence in situ hybridization, DNA index, and comparative genomic hybridization. Genes Chromosom Cancer 20:311–319 Watanabe T, Nobusawa S, Kleinhues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:n1149–n1153 Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891 Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306 Cairncross G, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479. doi:10.1093/jnci/90.19.1473 Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714. doi:10.1200/JCO.2005.04.3414 van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma- Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diag- nosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715–2722. doi:10.1200/JCO.2005.04.6078 Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t (1; 19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861. doi:10.1158/0008-5472. CAN-06-1796 Arslantas A, Artan S, Oner U, Müslümanoğlu H, Durmaz R, Cosan E, Atasoy MA, Basaran N, Tel E (2004) The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev 27:58–64 Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG (2001) Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158(3):1137–1143 Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG (2003) Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet 142(1):1–7. doi:10.1016/S0165-4608(02)00791-4 Hirose Y, Sasaki H, Miwa T, Ohba S, Ikeda E, Abe M, Ikeda S, Kobayashi M, Kawase T, Hasegawa M, Yoshida K (2011) Whole genome analysis from microdissected tissue revealed adult supratentorial grade II–III gliomas are divided into clinically relevant subgroups by genetic profile. Neurosurgery 69(2):376–390 Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683–7688 Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, von Deimling A (1995) Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91–95 Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Weistler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161(1):313–319 Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins R (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152 Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645 Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629 Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neuro-Oncol 34:37–59 Kim JW, Park CK, Park SH, Kim YH, Han JH, Kim CY, Sohn CH, Chang KH, Jung HW (2011) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82(2):224–227 Koeller KK, Rushing EJ (2005) From the archives of the AFIP: oligodendroglioma and its variants: radiologic–pathologic correlation. Radiographics 25:1669–1688 Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Crinière E, Capelle L, Duffau H, Cornu P, Broet P, Kujas M, Mokhtari K, Carpentier A, Sanson M, Hoang-Xuan K, Thillet J, Dlattre JY (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63:2360–2362 Sherman JH, Prevedello DM, Shah L, Raghavan P, Pouratian N, Starke RM, Lopes MB, Shaffrey ME, Schiff D (2010) MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien) 152(11):1827–1834 Talos IF, Zou KH, Ohno-Machado L, Bhagwat JG, Kikinis R, Black PM, Jolesz FA (2006) Supratentorial low-grade glioma resectability: statistical predictive analysis based on anatomic MR features and tumor characteristics. Radiology 239:506–513 Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61(18):6713–6715 Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353(8):811–822 Vergani F, Martino J, Gozé C, Rigau V, Duffau H (2011) World Health Organization grade II gliomas and subventricular zone: anatomic, genetic, and clinical considerations. Neurosurgery 68(5):1293–1298 Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626 van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6(5):421–430 Anja S, Hugues D (2011) Seizures and the natural history of World Health Organization grade II gliomas: a review. Neurosurgery 68:1326–1333. doi:10.1227/NEU.0b013e31820c3419 Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Boggs C, Schltz C, Mehta M (2009) Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed oligoastrocytomas : RTOG BR0131. Neuro Oncol 11(2):167–175 Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Crinière E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broët P, Sanson M, Delattre JY (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138